Literature DB >> 23744524

How pharmaceutical industry employees manage competing commitments in the face of public criticism.

Wendy Lipworth1, Kathleen Montgomery, Miles Little.   

Abstract

The pharmaceutical industry has been criticised for pervasive misconduct. These concerns have generally resulted in increasing regulation. While such regulation is no doubt necessary, it tends to assume that everyone working for pharmaceutical companies is equally motivated by commerce, without much understanding of the specific views and experiences of those who work in different parts of the industry. In order to gain a more nuanced picture of the work that goes on in the "medical affairs" departments of pharmaceutical companies, we conducted 15 semi-structured interviews with professionals working in medical departments of companies in Sydney, Australia. We show that this group of pharmaceutical professionals are committed to their responsibilities both to patients, research participants, and the public and to their companies. Despite the discrepancies between these commitments, our participants did not express much cognitive dissonance, and this appeared to stem from their use of two dialectically related strategies, one of which embraces commerce and the other of which resists the commercial imperative. We interpret these findings through the lens of institutional theory and consider their implications for pharmaceutical ethics and governance.

Entities:  

Mesh:

Year:  2013        PMID: 23744524     DOI: 10.1007/s11673-013-9449-4

Source DB:  PubMed          Journal:  J Bioeth Inq        ISSN: 1176-7529            Impact factor:   1.352


  21 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  Doctors as managers: investors and reluctants in a dual role.

Authors:  Tom Forbes; Jerry Hallier; Lorna Kelly
Journal:  Health Serv Manage Res       Date:  2004-08

3.  Doctors and management--the development dilemma.

Authors:  J Gatrell; T White
Journal:  J Manag Med       Date:  1996

4.  Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines.

Authors:  N Wang; W L Lipworth; J E Ritchie; K M Williams; R O Day
Journal:  Intern Med J       Date:  2011-04       Impact factor: 2.048

5.  Co-operation between patient organisations and the drug industry in Finland.

Authors:  Elina Hemminki; Hanna K Toiviainen; Lauri Vuorenkoski
Journal:  Soc Sci Med       Date:  2010-02-12       Impact factor: 4.634

6.  Pharmaceutical virtue.

Authors:  Emily Martin
Journal:  Cult Med Psychiatry       Date:  2006-06

7.  Direct-to-consumer advertising under the radar: the need for realistic drugs policy in Australia.

Authors:  F J Mackenzie; C F C Jordens; R A Ankeny; J McPhee; I H Kerridge
Journal:  Intern Med J       Date:  2007-04       Impact factor: 2.048

8.  Shifts in guidelines for ethical scientific conduct: how public and private organizations create and change norms of research integrity.

Authors:  Kathleen Montgomery; Amalya L Oliver
Journal:  Soc Stud Sci       Date:  2009-02       Impact factor: 3.885

9.  Doctors who become chief executives in the NHS: from keen amateurs to skilled professionals.

Authors:  Chris Ham; John Clark; Peter Spurgeon; Helen Dickinson; Kirsten Armit
Journal:  J R Soc Med       Date:  2011-03       Impact factor: 5.344

10.  The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.

Authors:  Hina Laeeque; Heather Boon; Natasha Kachan; Jillian Clare Cohen; Joseph D'Cruz
Journal:  BMC Health Serv Res       Date:  2006-05-31       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.